EUVIMEDEUVIMED entdecken
Crossref

Engineered hybrid cell membrane nanovesicles for potentiated cancer immunotherapy through dual immune checkpoint inhibition

Fuxu Yang, Han Xue, Yuxin Fan, Ting Zhang, Ting Wang, Fanlin Gu, Longxue Guan, Lisha Zhou, Xingang Guan, Guofu Chen

Biomaterials Science · 2025

DOI: 10.1039/d5bm00298b ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomaterials Science, 2025. Verfasst von Fuxu Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou 317500, PR C…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Lymphocyte Activation Gene 3 Protein, Nanoparticle Drug Delivery System. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Taizhou Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we developed a PD-1/LAG-3 receptors-decorated cell membrane nanovesicle for combination immunotherapy in colorectal cancer. The hybrid nanovesicle substantially inhibited tumor growth and elicited a robust antitumor immune response in MC38 xenograft-bearing mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsImmunotherapyLymphocyte Activation Gene 3 ProteinNanoparticle Drug Delivery SystemProgrammed Cell Death 1 ReceptorAnimalsHumansMiceCell Line, TumorExtracellular VesiclesHEK293 CellsNanostructuresRandom AllocationXenograft Model Antitumor AssaysColorectal Neoplasms

Substanzen

Immune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinNanoparticle Drug Delivery SystemProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • The First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou 317500, PR China. lishazhou@tzc.edu.cn.
  • College of Medical Technology, Beihua University, Jilin 132013, PR China.

Förderung

  • Natural Science Foundation of Zhejiang Province
  • Taizhou Municipal Science and Technology Bureau

Zitieren

APA

Yang, F., Xue, H., Fan, Y., Zhang, T., Wang, T., Gu, F., Guan, L., Zhou, L., Guan, X., & Chen, G. (2025). Engineered hybrid cell membrane nanovesicles for potentiated cancer immunotherapy through dual immune checkpoint inhibition. Biomaterials Science. https://doi.org/10.1039/d5bm00298b

Vancouver

Yang F, Xue H, Fan Y, Zhang T, Wang T, Gu F, et al. Engineered hybrid cell membrane nanovesicles for potentiated cancer immunotherapy through dual immune checkpoint inhibition. Biomaterials Science. 2025. doi:10.1039/d5bm00298b

BibTeX
@article{Yang2025,
  author = {Yang, Fuxu and Xue, Han and Fan, Yuxin and Zhang, Ting and Wang, Ting and Gu, Fanlin and Guan, Longxue and Zhou, Lisha and Guan, Xingang and Chen, Guofu},
  title = {Engineered hybrid cell membrane nanovesicles for potentiated cancer immunotherapy through dual immune checkpoint inhibition},
  journal = {Biomaterials Science},
  year = {2025},
  doi = {10.1039/d5bm00298b}
}
Kostenlos starten →